TerminatedNot Applicable

PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)

United States40 participantsStarted 2007-04-09

Plain-language summary

The purpose of this protocol is to measure a receptor in the brain using positron emission tomography (PET) that is involved in inflammation.

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. HIV-seropositive based on ELISA and Western blot (except the HIV-seronegative subjects, who will have ELISA screening).
✓. Capable of providing informed consent.
✓. Ambulatory at initial visit.
✓. If cognitively impaired, the degree of impairment will be MCMD, and not frank HIV-associated dementia.

✕. Current psychiatric illness or severe systemic disease based on history and physical exam
✕. Current dependence on alcohol or substances other than nicotine.
✕. Laboratory results from blood or urine tests that show clinically significant abnormalities.
✕. Previous radiation exposure (X-rays, PET scans etc.) that would exceed research limits.
✕. Pregnancy and breast feeding.
✕. A history of brain disease.
✕. Cannot lie on your back for long periods since the pictures will be taken for about 2.5 hours during which time you will have to lie still on the scanner bed.
✕. More than moderate hypertension.

Brain uptake of [11C]PBR28 (measured as distribution volume).

Timeframe: One brain PET scan in one outpatient visit to NIH per subject.

NCT IDNCT00459693

SponsorNational Institute of Mental Health (NIMH)

Sponsor typeNIH

Study typeINTERVENTIONAL

Primary completion2014-04-06